PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

38,389 stories, page 269 of 640

Advanced search
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT04321876: Evaluation of a Collaborative Behavioral Health Program Implementation in Primary Care

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT03652545: Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT03436485: Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

The 50 best-funded biotech companies of 2026

drugdiscoverytrends.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Regeneron Oncology Marketing Lead Sarah Ghosh Details Strategy for Adapting Global Pharmaceutical Narratives

geneonline.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Here's Why We Think DAE HWA Pharmaceutical (KOSDAQ:067080) Might Deserve Your Attention Today

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Celcuity Reports Q2 2026 Form 10-Q Highlighting FDA-Approved REVTORPYK and Ongoing Clinical Trials

Kalkine MediaOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Neurocrine affirms safety of Prader-Willi drug as it comes under scrutiny

FirstWord PharmaOriginal source
🌍Industryeikontx.comTier 1 · Company source

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon TherapeuticsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers SquibbOriginal source
🇺🇸Industrybristolmyers2016ir.q4web.comTier 3 · Secondary coverage

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol-Myers Squibb NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fortress Biotech: Q2 Earnings Snapshot

KTVBOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

TradingViewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Edesa Starts Activating First Vitiligo Trial Sites as Enrollment Nears

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Yahoo FinanceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

The Manila TimesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Crystalys Raises $130M to Advance Its Once-Daily Gout Drug

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewswireOriginal source
🌍Industryinvestors.vivani.comTier 1 · Company source

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani MedicalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock

Investor's Business DailyOriginal source
🌍Mediacryopak.comTier 2 · Direct publisher

Why Donor Human Milk Matters: What NICUs Need to Know

CryopakOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

2026 Emerging Pharma Leaders Award Winners Announced | PharmExec

Pharmaceutical ExecutiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies

The Manila TimesOriginal source
🇺🇸CROadvarra.comTier 2 · Direct publisher

What Is the Difference Between Monitoring and Auditing in Clinical Trials And Why Do They Matter for Inspection Readiness?

Advarra (IRB)Original source
🌍Industryapple.comTier 1 · Company source

Apple opens Advanced Manufacturing Center in Houston

Apple Health NewsroomOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

MarketBeatOriginal source
🌍Industrycormedix.comTier 1 · Company source

CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CorMedixOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Again acquires industrial biotech veteran Genomatica

Chemical & Engineering NewsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Healthcare Stocks Drifted Lower As Biotech Names Split

FinimizeOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

DBN targets 30% of Brazil’s soybean biotech market

Valor InternationalOriginal source
🇪🇸Researchcnio.esTier 2 · Direct publisher

What if cancer treatment came with a yogurt?

CNIO (Spain Cancer News)Original source
🌍discoverynews.google.comTier 3 · Aggregated media

Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway

Stock TitanOriginal source
🇺🇸Regulatoryciscrp.orgTier 1 · Regulatory source

New NIH Policy: Your Guide for Plain Language Study Results

CISCRP Patient InfoOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

A Common Drug Offers New Hope to People With Severe Hair Loss

NewsweekOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Who Is Policing the Retatrutide Bootleggers?

RealClearHealthOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Definium’s DT120 Meets Primary Endpoint in Phase 3 Anxiety Trial

clinicaltrialvanguard.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

New Pappas-backed fund targets promising agtech companies

The Business JournalsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Q&A: Amy Niles on Patient Access Reform in 2026

pharmaceuticalcommerce.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pilot Project Between BioCytics and LIDE Biotech

PR NewswireOriginal source
🇺🇸CROwcgclinical.comTier 2 · Direct publisher

Navigating Protocol Amendments: Understanding the Growing Burden and Charting a Path Forward

WCG (IRB)Original source
🇺🇸Devicesorthopediatrics.comTier 1 · Company source

Hinge Pediatric Plating System™

OrthoPediatricsOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA tracking 18 active outbreaks

foodsafetynews.comOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Cryptosporidium: national laboratory data

Annual data of reported Cryptosporidium infections in England since 2014.

UK Health Security AgencyOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Cryptosporidiosis: guidance, data and analysis

The characteristics, management and epidemiology of cryptosporidiosis.

UK Health Security AgencyOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Health protection Part 2A orders

Anonymised summaries of the use of statutory Part 2A orders to protect public health for the financi...

UK Health Security AgencyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

JW Pharmaceutical Proves Efficacy of Key 6mg Dose of Gout Treatment ‘Epaminurad’ in Multinational Phase 3 Trial

StreetInsiderOriginal source
🇯🇵Researchriken.jpTier 2 · Direct publisher

Planned shutdown of SPring-8 for SPring-8-II upgrade

RIKENOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA Warns Against Fake Agents Seeking Money For Food & Drug Licences

freepressjournal.inOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

NeuroSense details Phase 3 ALS plans and Nasdaq risks | NRSN SEC Filing - Form 6-K

Stock TitanOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Eli Lilly targets booming black market for retatrutide

STATOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Chugai Pharmaceutical Stock And 2 Japan Picks Trading Below Cash Flow Value

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High After Analyst Upgrade

MarketBeatOriginal source
🌍Regulatorynafdac.gov.ngTier 1 · Regulatory source

Regulatory Clarification on Deleject Disposable Needle Public Alert

NAFDAC NigeriaOriginal source